Chemfab Alkalis Ltd
Incorproated in 2009, Chemfab
Alkalis Ltd manufactures basic
inorganic chemicals and PVCO
pipes[1]
- Market Cap ₹ 582 Cr.
- Current Price ₹ 405
- High / Low ₹ 1,042 / 372
- Stock P/E
- Book Value ₹ 264
- Dividend Yield 0.31 %
- ROCE 3.32 %
- ROE 2.33 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 10.3% over past five years.
- Company has a low return on equity of 9.39% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Commodity Chemicals
Part of BSE Allcap BSE Commodities
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| 205 | 181 | 272 | 331 | 327 | 334 | 329 | |
| 149 | 157 | 215 | 221 | 273 | 290 | 297 | |
| Operating Profit | 55 | 24 | 57 | 111 | 55 | 44 | 32 |
| OPM % | 27% | 13% | 21% | 33% | 17% | 13% | 10% |
| -0 | 1 | 6 | 2 | 9 | -3 | -3 | |
| Interest | 4 | 3 | 1 | 1 | 2 | 6 | 7 |
| Depreciation | 25 | 20 | 22 | 23 | 22 | 36 | 31 |
| Profit before tax | 27 | 2 | 39 | 89 | 39 | -0 | -9 |
| Tax % | 5% | 500% | 26% | 28% | 33% | 2,210% | |
| 25 | -8 | 29 | 65 | 26 | -7 | -13 | |
| EPS in Rs | 18.26 | -5.78 | 20.34 | 45.54 | 18.50 | -4.83 | -9.12 |
| Dividend Payout % | 7% | 0% | 6% | 3% | 7% | -26% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | 7% |
| TTM: | 1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -20% |
| 3 Years: | -32% |
| TTM: | -166% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 25% |
| 3 Years: | 17% |
| 1 Year: | -59% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 9% |
| Last Year: | 2% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Reserves | 262 | 253 | 284 | 347 | 373 | 366 | 365 |
| 43 | 32 | 9 | 2 | 20 | 84 | 109 | |
| 30 | 36 | 46 | 48 | 93 | 57 | 79 | |
| Total Liabilities | 348 | 335 | 352 | 412 | 500 | 522 | 567 |
| 195 | 202 | 194 | 192 | 247 | 317 | 314 | |
| CWIP | 35 | 3 | 8 | 31 | 74 | 36 | 63 |
| Investments | 1 | 24 | 31 | 68 | 5 | 16 | 0 |
| 118 | 105 | 119 | 121 | 174 | 152 | 190 | |
| Total Assets | 348 | 335 | 352 | 412 | 500 | 522 | 567 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 54 | 45 | 55 | 93 | 31 | 40 | |
| -58 | -6 | -21 | -48 | -110 | -86 | |
| 3 | -16 | -25 | -9 | 16 | 59 | |
| Net Cash Flow | -1 | 23 | 9 | 36 | -62 | 13 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 17 | 31 | 29 | 24 | 24 | 23 |
| Inventory Days | 84 | 79 | 54 | 89 | 60 | 100 |
| Days Payable | 165 | 154 | 92 | 145 | 101 | 118 |
| Cash Conversion Cycle | -63 | -45 | -9 | -32 | -18 | 4 |
| Working Capital Days | -2 | 15 | 5 | 7 | -24 | 28 |
| ROCE % | 2% | 13% | 28% | 11% | 3% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
19h - Submission of newspaper clippings on publication of unaudited financial results for the quarter and nine months ended 31st December, 2025
-
Submission Of Investor Presentation
2d - Submission of investor presentation for the quarter ended 31st December, 2025
-
Results-Delay in Financial Results
2d - Approved standalone and consolidated unaudited results for quarter and nine months ended 31 Dec 2025.
-
Board Meeting Outcome for Intimation Of Outcome Of Board Meeting Held On 28.01.2026
2d - Board approved unaudited standalone and consolidated results for quarter and nine months ended 31 Dec 2025; reviewed by Deloitte.
-
Board Meeting Intimation for Board Meeting Intimation For Approving Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December, 31 2025 Among Other Items.
22 Jan - Board meeting 28 Jan 2026 to approve unaudited Q3/9M results ended 31 Dec 2025; trading window closed Jan 1–30, 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
CAL is an ISO 14001 and OHSAS 18001 certified manufacturer of choloro alkali products. It uses Membrane Technology for Chloralkali production. Company also produces chlorine, hydrogen, sodium hypo chlorite, and hydrochloric acid as by-products from manufacture of caustic soda